Danske Bank A S Sells 153,189 Shares of Edwards Lifesciences Corporation $EW

Danske Bank A S reduced its holdings in shares of Edwards Lifesciences Corporation (NYSE:EW – Free Report) by 29.2% during the 3rd quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 371,301 shares of the medical research company’s stock after selling 153,189 shares during the period. Danske Bank A S’s holdings in Edwards Lifesciences were worth $32,051,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds have also added to or reduced their stakes in the business. BlackRock Inc. acquired a new position in Edwards Lifesciences in the second quarter worth about $5,318,092,000. Bank of New York Mellon Corp acquired a new stake in Edwards Lifesciences during the second quarter valued at approximately $1,274,082,000. Bank of America Corp DE acquired a new stake in Edwards Lifesciences during the second quarter valued at approximately $605,397,000. Deutsche Bank AG bought a new stake in shares of Edwards Lifesciences in the 2nd quarter valued at approximately $516,552,000. Finally, UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC grew its stake in shares of Edwards Lifesciences by 0.6% in the 2nd quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 5,488,643 shares of the medical research company’s stock valued at $496,503,000 after purchasing an additional 30,495 shares during the period. Institutional investors own 79.46% of the company’s stock.

Edwards Lifesciences Price Performance

NYSE:EW opened at $106.95 on Tuesday. The firm has a market cap of $61.50 billion, a PE ratio of 35.99, a price-to-earnings-growth ratio of 2.82 and a beta of 0.85. Edwards Lifesciences Corporation has a 12 month low of $74.66 and a 12 month high of $108.00. The company has a quick ratio of 3.86, a current ratio of 4.60 and a debt-to-equity ratio of 0.05. The company’s 50-day moving average price is $90.76 and its two-hundred day moving average price is $86.44.

Edwards Lifesciences (NYSE:EW – Get Free Report) last posted its quarterly earnings data on Wednesday, November 4th. The medical research company reported $0.80 earnings per share for the quarter, topping the consensus estimate of $0.74 by $0.06. The company had revenue of $1.72 billion during the quarter, compared to analyst estimates of $1.68 billion. Edwards Lifesciences had a net margin of 15.30% and a return on equity of 16.06%. The company’s revenue was up 10.5% on a year-over-year basis. During the same quarter last year, the business posted $0.67 earnings per share. On average, equities analysts anticipate that Edwards Lifesciences Corporation will post 3.01 EPS for the current fiscal year.

Analysts Set New Price Targets

A number of equities analysts have recently issued reports on the company. Argus increased their target price on Edwards Lifesciences from $105.00 to $115.00 and gave the stock a “buy” rating in a report on Friday, August 21st. Robert W. Baird raised Edwards Lifesciences from a “neutral” rating to an “outperform” rating and set a $116.00 price target on the stock in a research note on Thursday, November 5th. Truist Financial set a $113.00 price target on Edwards Lifesciences and gave the company a “buy” rating in a research report on Wednesday, November 4th. BTIG Research upped their price target on Edwards Lifesciences from $110.00 to $115.00 and gave the company a “buy” rating in a research report on Thursday, November 5th. Finally, Mizuho set a $120.00 price objective on Edwards Lifesciences in a research note on Thursday, November 5th. Twenty-three equities research analysts have rated the stock with a Buy rating and three have assigned a Hold rating to the company’s stock. According to MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of $109.88.

Check Out Our Latest Report on Edwards Lifesciences

Insiders Place Their Bets

In related news, VP Donald E. Bobo, Jr. sold 48,900 shares of the firm’s stock in a transaction on Monday, November 9th. The stock was sold at an average price of $103.05, for a total transaction of $5,039,145.00. Following the completion of the sale, the vice president directly owned 22,798 shares of the company’s stock, valued at $2,349,333.90. This trade represents a 68.20% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, VP Annette Brüls sold 2,644 shares of Edwards Lifesciences stock in a transaction on Friday, August 28th. The shares were sold at an average price of $89.98, for a total value of $237,907.12. Following the completion of the transaction, the vice president owned 17,984 shares of the company’s stock, valued at approximately $1,618,200.32. The trade was a 12.82% decrease in their position. The SEC filing for this sale provides additional information. Insiders sold 53,945 shares of company stock valued at $5,498,306 over the last quarter. 0.31% of the stock is owned by insiders.

Edwards Lifesciences Company Profile

(Free Report)

Edwards Lifesciences is a medical technology company focused on therapies for structural heart disease and critical care. Its products include transcatheter and surgical heart valves, as well as technologies used to monitor patients during intensive care and surgery. The company traces its origins to 1958, when engineer Lowell Edwards and surgeon Albert Starr began developing an artificial heart valve. Their work led to the Starr-Edwards valve, introduced in 1960. Edwards Lifesciences is headquartered in Irvine, California, and serves clinicians and patients around the world.

Further Reading

Want to see what other hedge funds are holding EW? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Edwards Lifesciences Corporation (NYSE:EW – Free Report).

Institutional Ownership by Quarter for Edwards Lifesciences (NYSE:EW)

Receive News & Ratings for Edwards Lifesciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Edwards Lifesciences and related companies with MarketBeat.com's FREE daily email newsletter.